Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 1977 | 6.81 |
09:38 ET | 500 | 6.9 |
09:41 ET | 300 | 6.92 |
09:43 ET | 200 | 6.78 |
09:45 ET | 100 | 6.91 |
09:48 ET | 688 | 7.01 |
09:50 ET | 490 | 7.01 |
09:52 ET | 100 | 7 |
09:54 ET | 490 | 7 |
09:59 ET | 590 | 7 |
10:01 ET | 1021 | 6.94 |
10:03 ET | 2529 | 6.945 |
10:06 ET | 1100 | 6.96 |
10:08 ET | 961 | 7.005 |
10:12 ET | 320 | 6.97 |
10:14 ET | 264 | 7 |
10:15 ET | 200 | 7 |
10:19 ET | 1684 | 7 |
10:21 ET | 947 | 6.99 |
10:24 ET | 490 | 6.99 |
10:32 ET | 500 | 7.03 |
10:33 ET | 569 | 6.992 |
10:35 ET | 400 | 6.9718 |
10:44 ET | 200 | 6.94 |
10:50 ET | 4395 | 6.895 |
10:51 ET | 100 | 6.91 |
10:55 ET | 100 | 6.98 |
11:00 ET | 3700 | 6.88 |
11:02 ET | 362 | 6.8717 |
11:11 ET | 111 | 6.9154 |
11:13 ET | 804 | 6.82 |
11:15 ET | 200 | 6.8352 |
11:24 ET | 395 | 6.84 |
11:27 ET | 453 | 6.83 |
11:29 ET | 1428 | 6.8 |
11:31 ET | 1345 | 6.8 |
11:33 ET | 100 | 6.79 |
11:36 ET | 5911 | 6.86 |
11:40 ET | 1414 | 6.7834 |
11:51 ET | 100 | 6.85 |
12:00 ET | 2247 | 6.85 |
12:07 ET | 866 | 6.829 |
12:12 ET | 146 | 6.831812 |
12:18 ET | 100 | 6.835 |
12:27 ET | 800 | 6.84 |
12:30 ET | 100 | 6.82 |
12:32 ET | 500 | 6.84 |
12:38 ET | 2180 | 6.8 |
12:41 ET | 1048 | 6.78 |
12:52 ET | 200 | 6.74 |
12:57 ET | 2907 | 6.77 |
12:59 ET | 2000 | 6.789 |
01:01 ET | 5739 | 6.85 |
01:06 ET | 300 | 6.815 |
01:10 ET | 100 | 6.83 |
01:15 ET | 200 | 6.82 |
01:17 ET | 600 | 6.77 |
01:19 ET | 100 | 6.78 |
01:21 ET | 280 | 6.8166 |
01:24 ET | 300 | 6.77 |
01:28 ET | 100 | 6.78 |
01:30 ET | 300 | 6.78 |
01:32 ET | 727 | 6.77 |
01:33 ET | 100 | 6.75 |
01:35 ET | 100 | 6.765 |
01:37 ET | 1100 | 6.765 |
01:39 ET | 1000 | 6.765 |
01:42 ET | 545 | 6.765 |
01:44 ET | 100 | 6.76 |
01:46 ET | 100 | 6.74 |
01:48 ET | 494 | 6.7151 |
01:50 ET | 100 | 6.7 |
01:51 ET | 100 | 6.72 |
01:53 ET | 100 | 6.7 |
01:55 ET | 100 | 6.7346 |
01:57 ET | 100 | 6.7 |
02:02 ET | 100 | 6.7004 |
02:09 ET | 512 | 6.723232 |
02:11 ET | 100 | 6.7409 |
02:13 ET | 100 | 6.724 |
02:15 ET | 200 | 6.75 |
02:20 ET | 300 | 6.73 |
02:22 ET | 1200 | 6.75 |
02:31 ET | 100 | 6.73 |
02:36 ET | 1055 | 6.75 |
02:38 ET | 144 | 6.75 |
02:44 ET | 764 | 6.75 |
02:47 ET | 200 | 6.75 |
02:56 ET | 100 | 6.75 |
03:03 ET | 356 | 6.72 |
03:12 ET | 758 | 6.69 |
03:14 ET | 400 | 6.71 |
03:18 ET | 400 | 6.69 |
03:20 ET | 500 | 6.71 |
03:21 ET | 400 | 6.71 |
03:23 ET | 4374 | 6.67 |
03:27 ET | 450 | 6.69 |
03:30 ET | 226 | 6.68 |
03:32 ET | 100 | 6.685 |
03:36 ET | 333 | 6.68 |
03:38 ET | 100 | 6.66 |
03:39 ET | 200 | 6.69 |
03:41 ET | 200 | 6.72 |
03:43 ET | 931 | 6.73 |
03:45 ET | 277 | 6.74 |
03:48 ET | 100 | 6.75 |
03:50 ET | 100 | 6.75 |
03:52 ET | 308 | 6.73 |
03:56 ET | 100 | 6.74 |
03:57 ET | 200 | 6.74 |
03:59 ET | 14865 | 6.71 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 215.3M | -3.9x | --- |
XBiotech Inc | 214.8M | -6.1x | --- |
Acrivon Therapeutics Inc | 213.4M | -2.5x | --- |
Immutep Ltd | 310.4M | -8.6x | --- |
Trevi Therapeutics Inc | 219.2M | -7.8x | --- |
Omeros Corp | 219.6M | -1.1x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $215.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.